NCT07241546RecruitingPhase 2
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
A Randomized, Double-blind, Placebo-controlled Phase 2a Study of ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-induced Mild Asthma
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 17 Nov 2025
- Start date
- 30 Mar 2026
- Primary completion date
- Dec 2027
- Lead sponsor
- Arrowhead Pharmaceuticals
- Diseases
- Asthma
- NCT number
- NCT07241546
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 36
- From 30 Mar 2026 to the primary completion date, Dec 2027
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant diagnosis of a clinically important pulmonary disease other than asthma
Other illness
- Use of corticosteroids, immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma
- History or current medical condition contraindicating methacholine challenge
- Note: Additional inclusion/exclusion criteria may apply per protocol.
Who the study is looking for
- Clinically stable, mild atopic asthma (FEV1 ≥70% predicted)
- Established allergy confirmed by positive skin prick test at screening
- Willing and able to perform lung function tests and other study-related procedures
- Participants of childbearing potential must consent to use a method of highly-effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last investigational product administration, whichever is later
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Calgary | Canada | Recruiting |
| - Coordinator of this site? Confirm its status | Edmonton | Canada | Recruiting |
| - Coordinator of this site? Confirm its status | Hamilton | Canada | Recruiting |
| - Coordinator of this site? Confirm its status | Québec | Canada | Recruiting |
| - Coordinator of this site? Confirm its status | Saskatoon | Canada | Recruiting |
| - Coordinator of this site? Confirm its status | Vancouver | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.